Drug Discovery & Research

Persistent innovative development is one of the eminent characters of pharmaceutical industry. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage, giving rise to abundant but relatively dispersed knowledge of the mechanisms driving pharma drug discovery and development. The invention of new medicines, and the improvement of existing drugs constitute the development firms in pharmaceutical industry. The occasional triumph of creating a novel therapy in an area with no prior treatments counts among the pharmaceutical industry’s most defining hallmarks.
Germany is forecast to have highest increase in pharmaceutical market value at € 11.4bn. Novartis is forecast to reduce its pharma R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20 pharmaceutical industries, Celgene and Regeneron are forecast to grow their pharma R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total pharma R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022.
Persistent innovative development is one of the eminent characters of pharmaceutical industry. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage, giving rise to abundant but relatively dispersed knowledge of the mechanisms driving pharma drug discovery and development. The invention of new medicines, and the improvement of existing drugs constitute the development firms in pharmaceutical industry. The occasional triumph of creating a novel therapy in an area with no prior treatments counts among the pharmaceutical industry’s most defining hallmarks.
Germany is forecast to have highest increase in pharmaceutical market value at € 11.4bn. Novartis is forecast to reduce its pharma R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20 pharmaceutical industries, Celgene and Regeneron are forecast to grow their pharma R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total pharma R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022.
  • Challenges in Drug Discovery
  • Criteria for Target Selection
  • Advancements of In vitro studies
  • Enhancements of In vivo studies
  • Quality by Design
  • Random Screening
  • Molecular Designing
  • Drug Metabolites
  • Genomic Technologies
  • Proteomic Technologies
  • Nanotechnology
  • Microencapsulation: Methods and Industrial Applications

Related Conference of Drug Discovery & Research

September 20-21, 2017

10th Pharmacovigilance Congress

Charlotte, North Carolina, USA
September 25-26, 2017(10 Plenary Forums- 1 Event)

7th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR

Chicago, Illinois, USA
September 25-26, 2017
(10 Plenary Forums - 1Event)

6th International Conference and Exhibition on GMP, GCP & Quality Control

Chicago, Illinois, USA
October 02-04, 2017

World Congress on Antibiotics: R&D, Market

Atlanta, USA
October 16-18, 2017

12th World Pharma Congress

Budapest, Hungary
October 16-18, 2017

11th World Drug Delivery Summit

(10 Plenary Forums - 1Event)
Baltimore, Maryland, USA
October 16-17, 2017

10th International Conference and Exhibition on Biologics and Biosimilars

San Francisco, California, USA
November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Drug Discovery & Research Conference Speakers

Recommended Sessions

Related Journals

Are you interested in